Re: Campath Sells $16.5 Million Worth of Campath in 4 months

[Guest guest]

Dear , you recently posted an article about Campath and its effects etc,

but I have lost it.

Can you provide me with any info on this drug please.

Regards, Ian

Campath Sells $16.5 Million Worth of Campath in 4

months

ILEX Oncology Reports Q3 Net Sales of Campath of $11.2

Million

SAN ANTONIO--(BW HealthWire)--Oct. 11, 2001--ILEX

Oncology, Inc. (Nasdaq:ILXO) today reported that

global net sales of Campath® for the third quarter

of 2001 totaled $11.2 million. Year-to-date global net

sales of the recently approved humanized monoclonal

antibody reached $16.5 million for the four months

since the product's U.S. launch on May 30.

" We continue to receive positive feedback from

hematology and oncology physicians and nurses using

Campath and are pleased with the continued uptake of

the drug, " said ILEX Chief Executive Officer

Love. " Additionally, we and our partners have launched

MabCampath in both the United Kingdom and Germany

during the third quarter, following European

regulatory approval in July. "

__________________________________________________

[Guest guest]

FYI any mail posted to is available by

going to the archives at .

To get there, go to and click on

. That brings up a page with messages. Go

to the search box. Perhaps Campath would be the best

term to search on.

I will search and get back to you, although I'm not

exactly sure what message you are referring to...

--- Ian's Mail <ian.waterson@...> wrote:

> Dear , you recently posted an article about

> Campath and its effects etc, but I have lost it.

> Can you provide me with any info on this drug

> please.

> Regards, Ian

> Campath Sells $16.5 Million

> Worth of Campath in 4 months

>

>

> ILEX Oncology Reports Q3 Net Sales of Campath of

> $11.2

> Million

>

> SAN ANTONIO--(BW HealthWire)--Oct. 11, 2001--ILEX

> Oncology, Inc. (Nasdaq:ILXO) today reported that

> global net sales of Campath® for the third

> quarter

> of 2001 totaled $11.2 million. Year-to-date global

> net

> sales of the recently approved humanized

> monoclonal

> antibody reached $16.5 million for the four months

> since the product's U.S. launch on May 30.

>

> " We continue to receive positive feedback from

> hematology and oncology physicians and nurses

> using

> Campath and are pleased with the continued uptake

> of

> the drug, " said ILEX Chief Executive Officer

>

> Love. " Additionally, we and our partners have

> launched

> MabCampath in both the United Kingdom and

> Germany

> during the third quarter, following European

> regulatory approval in July. "

>

>

>

>

> __________________________________________________

>